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ess: francois.maltais@mSummary Abnormal heart rate recovery (HRR) after exercise, a marker of cardiac
autonomic dysfunction, is associated with poor prognosis in various populations. As
chronic obstructive pulmonary disease (COPD) is associated with cardiac autonomic
dysfunction, we tested the hypothesis that patients with COPD have a lower HRR
than healthy people, and evaluated whether a delay in HRR is associated with an
increased risk of mortality in COPD. The records of 147 COPD patients were reviewed
(65.179.1 years, mean7SD, 42 women/105 men, forced expiratory volume in 1 s
(FEV1): 42715% predicted) and compared to 25 healthy subjects (61.674.5 years, 5
women/20 men, FEV1: 100714% predicted) during recovery after an exercise test.
Heart rate was measured at peak exercise and at 1-min recovery, the difference
between the two being defined as HRR (1179 beats in COPD patients vs. 2079 beats
in healthy subjects, Po0:0001). During a mean follow-up of 43.1722.0 months, 32
patients died. Abnormal HRR (p14 beats) was a strong predictor of mortality in
COPD patients (adjusted hazard ratio: 5.12, 95% CI [1.54–17.00]). In conclusion,
COPD patients have a lower HRR than healthy subjects, and have a worse prognosis
when presenting abnormal HRR.
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Cardiac autonomic dysfunction has been documen-
ted in patients with chronic heart failure,1 dia-
betes,2 sleep apnea3 and obesity.4 Autonomic
dysfunction is thought to impact directly the
natural evolution of these diseases. For instance,
in chronic heart failure, reduced cardiac para-
sympathetic activity has been associated withed.
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ventricular arrhythmias, and poor prognosis.5
Chronic obstructive pulmonary disease (COPD) is a
major health problem in developed countries. In
2000, it was the fourth leading cause of death in the
United States,6 and its prevalence is still increasing.7
The main predictor of mortality in COPD is a low
forced expiratory volume in 1 s (FEV1) value. Other
prognostic markers in patients with COPD are age,
exercise capacity, resting heart rate,8 body weight9
and muscle mass.10 Compared to smokers with
normal lung function, those who developed COPD
are at increased risk of cardiovascular disease.
Interestingly, a low FEV1 is a strong predictor of all
cause mortality and of mortality from ischaemic
heart disease.11 The presence of low grade systemic
inflammation in COPD has recently been proposed as
a possible explanation for the increased risk of
cardiovascular disease in this condition.12
Cardiac autonomic dysfunction has recently been
observed in COPD, as evidenced by a decreased
heart rate response to the Valsalva maneuver and
to standing,13 a decreased heart rate variability,14 a
prolonged QTc interval
15 and an abnormality of left
ventricular sympathetic nervous function.16 We
therefore speculated that an abnormal cardiac
autonomic function, as in other chronic diseases,
may contribute to increase mortality in COPD.
In clinical practice, cardiac autonomic function is
not commonly evaluated in patients with COPD, since
the evaluating tools are not totally standardized,
tedious or not readily available. Interestingly, heart
rate recovery (HRR) immediately after exercise, which
is commonly monitored in the exercise laboratory, has
been recently used as a marker of the cardiac
autonomic function and is a powerful predictor of
mortality in various populations,17–21 independent of
workload and of changes in heart rate during
exercise.18 In a recent study, HRR has been found to
be delayed in patients with abnormal spirometry, most
of whom had COPD.22 In that study however, a possible
link between HRR and survival was not assessed.
The aims of this study were therefore to
evaluate; (1) whether HRR is lower in COPD
patients than in healthy subjects, and (2) if a
delayed HRR following exercise is associated with
increased mortality in patients with COPD.Methods
Subjects
This is a retrospective study in which the records
of the 208 COPD patients who were evaluated inour research exercise laboratory between April
1994 and September 2000 were initially reviewed.
Among them, those who met the following
inclusion criteria were considered as potential
participants: (1) diagnosis of COPD, based on
current or past smoking history, clinical evaluation,
and pulmonary function tests,23 (2) maximal ex-
ercise test performed in the exercise physiology
laboratory of our research center, (3) clinically
stable at the time of the exercise test without
symptomatic cardiovascular disease, uncontrolled
hypertension (X160/100), neurological, or any
other conditions that could impair capacity to
perform the exercise test or increase short-term
mortality. Patients were excluded if exercise and
recovery heart rate data were incomplete (because
of technical reasons making monitoring unavailable
during the whole 1-min recovery) or if cardiac
arrhythmias impaired the interpretation of HRR.
Finally, 147 patients were deemed eligible to this
study.
In order to compare HRR between healthy people
and COPD patients, 25 healthy subjects were also
recruited to perform the exercise test, but they
were not followed-up afterwards.
The consent to use this information in the
present study was granted by the local ethics
committee.Protocol
Pulmonary function tests. Standard pulmonary
function tests including spirometry and lung vo-
lumes were obtained according to previously
described guidelines,23 and compared to normal
values published by Knudson et al.24 and Goldman
and Becklake.25
Exercise test. After 3–5min of rest, a progressive
symptom-limited stepwise exercise test was per-
formed on a cycle ergometer. Each exercise step
lasted 1min; 10- and 20-W increments were used in
COPD and healthy subjects, respectively. After
exercise, a cool-down period during which patients
cycled against a reduced work rate was allowed.
Heart rate was monitored continuously during pre-
exercise (while seated on the ergocycle), exercise
and recovery with an electrocardiogram (Quinton
Q4500, Bothell, WA, USA). The mean values of
oxygen uptake ( _VO2), carbon dioxide excretion
( _VCO2) and ventilation (
_VE) were obtained at rest,
at peak exercise and after 1-min recovery (mean of
the last 15 s in each period). In most patients,
resting PaO2 and PaCO2 were measured with a blood
gas machine (AVL 995, AVL Scientific Corp, Roswell,
Georgia).
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Heart rate recovery COPD mortality 879Heart rate recovery. HRR was defined as the
difference between heart rate at peak exercise and
at one minute into the recovery period.
Survival status. The medical chart of each
patient was carefully reviewed. The survival status
and the date and cause of death were noted when
available. When it could not be established from
the medical chart, the information was obtained
from the Institut de la statistique du Que´bec, an
organization recording all deaths in the province of
Quebec.
Statistical analysis. Descriptive parameters were
used to describe the study population at baseline,
and data were compared using t-tests or Man-
n–Whitney rank sum test and Fischer’s exact test.
Age, the only non-disease-related personal char-
acteristic that was different between the two
groups, was used as a covariate in the analysis.
The threshold used to dichotomize abnormal from
normal HRR was based on the lower limit of the 95%
confidence interval of HRR in healthy subjects. We
then conducted univariate analyses based on the
Cox proportional hazards model using each of the
potential predictors of mortality in patients with
COPD as independent variables (age, gender, body
mass index, FEV1, resting PaO2 ; resting PaCO2 ; peak
work capacity, resting heart rate, abnormal HRR,
known coronary artery disease (CAD), and drug
regimen) and the survival status as the dependent
variable. Independent variables that were asso-
ciated with mortality in the univariate analyses
ðPo0:15Þ were then incorporated into a multi-
variate analysis also based on the Cox proportional
hazards model. Correlations were established using
the Pearson product moment. Statistical signifi-
cance was set at two-tailed 0.05 level. Analyses
were performed using SAS software, release 8.2
(SAS Institute Inc., Cary, NC, USA) and Sigma Stat
2.03 (Chicago, IL, USA).Results
Subject characteristics
The demographic, anthropometric, pulmonary
function and exercise characteristics of COPD
patients and healthy subjects are presented in
Table 1.
COPD patients were on standard bronchodilator
therapy and most were also on inhaled corticoster-
oid therapy. Some patients also used verapamil,
diltiazem or digoxin to treat high blood pressure,
CAD or arrhythmias. The percentage of patients
using each drug is shown in Table 2. The pharma-cological regimen was continued on the morning of
the test.
The mean follow-up duration was 43.1722.0
months up to May 2001 (range ¼ 1.7–86.0 months).
Thirty-two deaths occurred during this period,
representing a mortality rate of 22%. The causes
of death were the following: end-stage COPD
ðn ¼ 14Þ; ischemic heart disease ðn ¼ 5Þ; cancer
(n ¼ 7; including 2 deaths due to lung cancer),
cerebral hemorrhage ðn ¼ 1Þ; other causes ðn ¼ 5Þ:
The demographic, anthropometric, pulmonary
function and exercise characteristics of COPD
patients who survived and of those who did not
are presented in Table 3.
Heart rate recovery: healthy subjects versus
COPD patients
As the 95% confidence interval of HRR in healthy
subjects was 15–24 beats, the threshold for
abnormal HRR was then established at 14 beats;
thus a HRRp14 beats was considered abnormal.
HRR was significantly lower in patients with
COPD, and the difference persisted after adjust-
ment for age (COPD: 1179 beats; healthy subjects:
1979 beats, Po0:0001). Moreover, 66% of COPD
patients had a HRRp14 beats compared to 24% of
healthy subjects.
There was no significant correlation between
HRR and FEV1 in healthy subjects but there was a
weak correlation in COPD patients ðr ¼ 0:17; P ¼
0:047Þ: In healthy subjects, HRR correlated with
peak heart rate ðr ¼ 0:40; P ¼ 0:0495Þ but not with
peak work capacity ðr ¼ 0:20; P ¼ 0:34Þ: In COPD
patients, HRR moderately correlated with peak
work capacity ðr ¼ 0:37; Po0:0001Þ; resting heart
rate ðr ¼ 0:31; P ¼ 0:0002Þ and peak heart rate
ðr ¼ 0:26; P ¼ 0:002Þ: In COPD, HRR did not corre-
late with PaO2 ðr ¼ 0:09; P ¼ 0:31Þ:
Heart rate recovery and mortality in COPD
patients
COPD patients were dichotomized according to
their HRR: normal (HRR414 beats) and abnormal
(HRRp14 beats). Among the 32 patients who died
during follow-up, 29 (91%) had an abnormal HRR.
The characteristics of the two groups are shown in
Table 4.
Variables that were statistically associated with
mortality in the univariate analysis with a Po0:15
were FEV1, HRR, resting PaO2 ; peak work rate,
resting heart rate, age, and resting PaCO2(Table 5).
A stepwise regression analysis found FEV1 as the
major predictor of mortality (hazard ratio: 0.95,
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Table 1 Characteristics of COPD patients and healthy subjects.
COPD patients ðn ¼ 147Þ Healthy subjects ðn ¼ 25Þ P value
Age, years 65.179.1 61.674.5 0.004
Gender, F/M 42/105 5/20 0.47
Height, m 1.6470.09 1.7170.07 0.0004
Weight, kg 69.5716.6 78.5711.6 0.01
BMI, kg/m2 25.675.8 26.974.1 0.31
FEV1, % predicted 42715 100714 o0.0001
Resting PaO2 ; mmHg
 82712 9879 o0.0001
Resting PaCO2 ; mmHg
 4376 3873 0.009
Resting heart rate, bpm 85717 76713 0.01
Peak work capacity, % predicted 44720 111722 o0.0001
Peak METs 4.071.3 6.772.4 o0.0001
Peak _VO2 ; l/min
y 1.0070.43 1.9370.59 o0.0001
Peak _VCO2 ; l/min
y 0.9470.44 2.4070.70 o0.0001
Peak _VE; l/min
y 37.4714.9 78.0726.4 o0.0001
Resting tidal volume (l) 0.63770.246 N/A
Peak tidal volume (l) 1.08170.348 N/A
Tidal volume at 1min recovery (l) 1.12170.353 N/A
Heart rate recovery, beats 1179 2079 o0.0001
Abnormal HRR (p14 beats), n (%) 97 (66) 6 (24) o0.0001
Deaths, n (%) 32 (22) N/A
Continuous variables are presented as the means7SD; categorical variables are presented as n (%) of patients. COPD, chronic
obstructive pulmonary disease; BMI, body mass index; FEV1, forced expiratory volume in 1 s; PaO2 ; oxygen arterial pressure;
PaCO2 ; carbon dioxide arterial pressure; bpm, beats per minute;
_VO2 ; oxygen uptake;
_VCO2 ; carbon dioxide output;
_VE;
ventilation; HRR, heart rate recovery.
Obtained in 127 COPD patients and 14 healthy subjects, respectively.
yObtained in 143 COPD patients.
Table 2 COPD pharmacological regimen and
medication that could influence heart rate.
Drug Percentage
of users
Short-acting b2-agonists 88
Long-acting b2-agonists 23
Ipratropium bromide 65
Theophylline 29
Inhaled corticosteroids 64
Verapamil 5
Diltiazem 11
Digoxin 4
M. Lacasse et al.88095% confidence interval [0.91–0.98], P ¼ 0:005).
The hazard ratio value being lower than 1 indicates
that a greater FEV1 is protective against mortality.
Abnormal HRR, the only other significant covari-
ate in the Cox regression model, was associated
with a 5.12 fold increase in mortality when
compared to patients with normal HRR (95%
confidence interval [1.54–17.00], P ¼ 0:008)
(Table 6). Patients presenting both an abnormalHRR and FEV1o50% had a worse prognosis com-
pared to those with a normal HRR and FEV1o50%
ðP ¼ 0:0008Þ; and those with normal HRR and FEV1
X50% ðP ¼ 0:009Þ: Survival curves of patients with
abnormal HRR and those with normal HRR were
significantly different (Fig. 1), even when adjusted
for FEV1 (Fig. 2).
The association between various cut off points to
define an abnormal HRR and mortality was also
evaluated. Although the best cut off point for HRR
in the present study was 14, a strong association
between an abnormal HRR and mortality in the Cox
regression model was still evident when using all
HRR thresholds between 12 and 16: (12: hazard
ratio: 2.54, 95% confidence interval [1.08–5.98],
P ¼ 0:02; 13: hazard ratio: 3.94, 95% confidence
interval [1.36–11.37], P ¼ 0:03; 15: hazard ratio:
3.85, 95% confidence interval [1.16–12.79], P ¼
0:009; 16: hazard ratio: 2.98, 95% confidence
interval [0.90–9.87], P ¼ 0:04).
To evaluate whether certain personal character-
istics (known CAD; use of verapamil, diltiazem or
digoxin; use of bronchodilators) could explain the
increased mortality rate in patients with an
abnormal HRR, a number of subgroup analyses
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Table 3 Characteristics of alive vs. dead COPD patients.
Alive ðn ¼ 115Þ Dead ðn ¼ 32Þ P value
Age, years 64.679.3 66.678.5 0.33
Gender, F/M 31/84 11/21 0.51
Height, m 1.6570.09 1.6270.09 0.08
Weight, kg 70.6716.1 65.6717.8 0.13
BMI, kg/m2 25.875.6 24.976.3 0.24
FEV1, % predicted 45715 32711 o0.0001
Resting PaO2 ; mmHg
 83712 78713 0.06
Resting PaCO2 ; mmHg
 4175 4777 o0.001
Resting heart rate, bpm 84715 91720 0.02
Peak work capacity, % predicted 47721 37716 0.02
Peak METs 4.171.2 3.771.4 0.083
Peak _VO2 ; l/min
y 1.0370.41 0.8870.51 0.10
Peak _VCO2 ; l/min
y 0.9970.45 0.7770.32 0.02
Heart rate recovery, beats 11710 876 0.021
Abnormal HRR (p14 beats), n(%) 68 (59) 29 (91) 0.0006
Known coronary artery disease, n (%) 28 (24) 9 (28) 0.837
Continuous variables are presented as the means7SD; categorical variables are presented as n (%) of patients. COPD, chronic
obstructive pulmonary disease; BMI, body mass index; FEV1, forced expiratory volume in 1 s; PaO2 ; oxygen arterial pressure;
PaCO2 ; carbon dioxide arterial pressure; bpm, beats per minute;
_VO2 ; oxygen uptake;
_VCO2 ; carbon dioxide output; HRR, heart
rate recovery.
Obtained in 127 COPD patients.
yObtained in 143 COPD patients.
Table 4 Comparison between COPD patients with normal and abnormal heart rate recovery.
Abnormal
(p14 beats) ðn ¼ 97Þ
Normal
(414 beats) ðn ¼ 50Þ
P value
Age, years 66.677.8 62.1710.8 0.015
Gender, F/M 23/74 19/31 0.084
BMI, kg/m2 25.575.7 25.975.9 0.709
FEV1, % predicted 40715 46715 0.019
Resting PaO2 ; mmHg
 81712 83713 0.304
Resting PaCO2 ; mmHg
 4376 4277 0.313
Peak work capacity, % predicted 42720 50721 0.024
Breathing pattern
Resting respiratory rate (br/m) 2275 2075 0.062
Resting ventilation (l/min) 12.773.1 12.774.1 0.927
Resting tidal volume (l) 0.60970.215 0.67970.285 0.201
Peak respiratory rate (br/m) 3578 3577 0.868
Peak ventilation (l/min) 35.6714.2 40.1714.1 0.144
Peak tidal volume (l) 1.01970.303 1.11970.393 0.034
Respiratory rate at 1min recovery (br/m) 2975 3075 0.380
Ventilation at 1min recovery (l/min) 31.1711.0 34.1711.5 0.205
Tidal volume at 1min recovery (l) 1.08870.326 1.17070.391 0.282
Resting heart rate, bpm 89717 79713 0.0003
Heart rate recovery, beats 676 2075 0.001
Death, n (%) 29 (30) 3 (6) 0.0006
Continuous variables are presented as the means7SD; categorical variables are presented as n (%) of patients. BMI, body mass
index; FEV1, forced expiratory volume in 1 s; PaO2 ; oxygen arterial pressure; PaCO2 ; carbon dioxide arterial pressure; bpm, beats
per minute; br/m, breaths per minute.
Obtained in 86 and 41 patients with abnormal and normal heart rate recovery, respectively.
Heart rate recovery COPD mortality 881
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Table 5 Predictors of mortality: univariate analysis.
Hazard ratio 95% Confidence interval P value (likelihood ratio)
Gender, M 0.796 0.383–1.656 0.55
FEV1, % predicted 0.940 0.907–0.974 0.0001
Abnormal heart rate recovery, beats 7.315 2.223–24.072 0.001
Resting PaO2 ; mmHg
 0.975 0.943–1.009 0.13
BMI, kg/m2 0.978 0.913–1.047 0.51
Peak work capacity, % predicted 0.980 0.961–0.999 0.04
Resting heart rate, bpm 1.031 1.009–1.053 0.007
Age, years 1.032 0.988–1.078 0.14
Resting PaCO2 ; mmHg
 1.071 1.027–1.116 0.003
Long-acting b2-agonists 1.197 0.406–3.527 0.75
Known coronary artery disease 1.354 0.626–2.930 0.44
Calcium channel blockers 1.417 0.653–3.073 0.39
Anticholinergics 1.478 0.683–3.199 0.31
Short-acting b2-agonists 1.885 0.450–7.902 0.34
FEV1, forced expiratory volume in 1 s; PaO2 ; oxygen arterial pressure; BMI, body mass index; bpm, beats per minute; PaCO2 ;
carbon dioxide arterial pressure.
n ¼ 127.
Table 6 Multivariate analysis based on Cox-regression model: abnormal heart rate recovery adjusted for
confounding factors.
Hazard ratio 95% Confidence interval P value
Abnormal heart rate recovery, beats 5.12 1.54–17.00 0.008
FEV1, % predicted 0.95 0.91–0.98 0.005
FEV1, forced expiratory volume in 1 s.
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Figure 1 Survival curves of COPD patients with normal
and abnormal HRR. Survival curves based on the Cox
proportional hazard model and adjusted for FEV1 for
patients with normal or abnormal HRR. Survival was
significantly different between the two groups.
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Figure 2 Survival curves of COPD patients according to
HRR and FEV1. Survival curves based on the Kaplan-Meier
model for patients with normal or abnormal HRR.
Patients with abnormal HRR and FEV1o50% of predicted
value showed a significantly worse survival when com-
pared to those with normal HRR who presented a FEV1
o50% or X50% of predicted value.
M. Lacasse et al.882were performed. The presence of known CAD
(angina, myocardial infarction, angioplasty or
coronary artery bypass grafting) in 37 patients
could not explain the increased mortality rateassociated with abnormal HRR. First, the propor-
tion of alive or dead patients who had a known CAD
was similar. Second, known CAD was not a
ARTICLE IN PRESS
Table 7 Characteristics of COPD patients according to use of digoxin, verapamil or diltiazem.
Non-users ðn ¼ 120Þ Users ðn ¼ 27Þ P value
Age, years 64.679.5 67.177.1 0.20
Gender, F/M 37/82 4/23 0.11
BMI, kg/m2 25.275.7 27.875.6 0.03
FEV1, % predicted 41.8715.5 42.6714.9 0.82
Resting PaO2 ; mmHg
 83.0712.5 76.3711.4 0.02
Resting PaCO2 ; mmHg
 42.276.3 44.476.3 0.11
Resting heart rate, bpm 85716 86719 0.80
Peak work capacity, % predicted 44721 47717 0.45
Peak _VO2 ; l/min
y 0.9670.39 1.1670.56 0.09
Peak _VCO2 ; l/min
y 0.9370.43 1.0470.41 0.23
Heart rate recovery, beats 11710 876 0.05
Abnormal HRR (p14 beats), n(%) 74 (62) 22 (81) 0.07
Deaths, n(%) 24 (20) 8 (30) 0.31
Continuous variables are presented as the means7SD; categorical variables are presented as n (%) of patients. COPD, chronic
obstructive pulmonary disease; BMI, body mass index; FEV1, forced expiratory volume in 1 s; PaO2 ; oxygen arterial pressure;
PaCO2 ; carbon dioxide arterial pressure; bpm, beats per minute;
_VO2 ; oxygen uptake;
_VCO2 ; carbon dioxide output; HRR, heart
rate recovery.
Obtained in 127 COPD patients.
yObtained in 143 COPD patients.
Heart rate recovery COPD mortality 883significant predictor of mortality in the univariate
anaylsis (Table 5). Third, an abnormal HRR still
predicted mortality when CAD patients were
excluded from the analysis (hazard ratio: 5.92,
95% confidence interval [1.74–20.00], P ¼ 0:004).
Patients using verapamil, diltiazem and digoxin
ðn ¼ 27Þ were compared with non-users: there was
no significant difference in age, gender, FEV1, peak
work capacity, resting heart rate and number of
deaths between the two groups (Table 7). HRR
tended to be lower in users (876 vs. 11710 beats,
P ¼ 0:05), but survival curves did not differ
significantly between the two groups ðP ¼ 0:25Þ:
Moreover, HRR was still a predictor of mortality
when analyzing only non-users (adjusted hazard
ratio: 4.40, 95% confidence interval [1.29–15.01],
P ¼ 0:02). Bronchodilators (short and long acting
b2-agonists and theophylline) and inhaled corticos-
teroids had no significant impact on mortality or
HRR, except for anticholinergics, which were
associated with a lower HRR only in the univariate
analysis (users: 979 beats; non-users: 13710
beats; P ¼ 0:01). Nevertheless, anticholinergic use
was not significantly different between patients
with normal and abnormal HRR.Discussion
The present study confirms the recently reported
finding that in patients with abnormal spirometry,HRR after exercise is slower than in healthy
subjects. Our study further extends this notion by
showing that an abnormal HRR is associated with
increased mortality rate in COPD.
HRR following exercise, an easily measurable
parameter during an exercise test, is thought to be
mediated mostly by the reactivation of the para-
sympathetic nervous system,18,26 a decreased HRR
thus reflecting a lower parasympathetic activity. It
is also less cumbersome than most other tests
assessing parasympathetic nervous function, such
as heart rate response to Valsalva maneuver, heart
rate variation during deep breathing and heart rate
response to standing.27 Physicians will also find it
easier to interpret than heart rate variability
recordings.
Using a HRR cut off point of 12 as previously
proposed,18 Seshadri et al. reported that a low FEV1
was associated with an abnormal HRR in patients
with either obstructive or restrictive ventilatory
defect.22 However, the potential prognostic implica-
tion of this finding was not addressed by these
authors. In the present study, we intended to
evaluate the HRR specifically in patients with COPD
and to assess the prognostic implication of a low HRR
in this population. Despite differences in the study
population and in the cut off used to define an
abnormally low HRR, Seshadri’s conclusion and ours
are strikingly similar in showing that an abnormal
HRR is a common finding in advanced COPD.
An important implication of our results is that a
delayed HRR is associated with poorer prognosis in
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M. Lacasse et al.884COPD. The most common cause of mortality in the
present study was end-stage COPD; this is not
unexpected given that our patients had on average
severe airflow obstruction (mean FEV1 of 42%
predicted value). The number of cardiovascular
deaths in this study was too small to determine
whether an abnormal HRR could also predict
cardiovascular diseases-related mortality in COPD.
Nevertheless, our data suggest that an abnormal
HRR may be useful in the clinical assessment of
patients with COPD since it is associated with all-
cause mortality. It should also be noted that
cardiovascular disease is a more prevalent cause
of mortality than respiratory failure in patient with
mild to moderate COPD 28,29 and that the presence
of COPD in itself is a risk factor for cardiovascular
disease independent from the smoking history.11,12
It is therefore tempting to speculate that the
assessment of cardiac autonomic function could be
particularly useful in this category of COPD.Pathophysiological mechanisms of cardiac
autonomic dysfunction
Although our study was not designed to address the
origins of this reduced vagal activity, several
mechanisms have been put forward to explain
autonomic dysfunction in COPD. Cardiac autonomic
dysfunction in COPD may either be due to a
decreased parasympathetic activity,13,15,30 an in-
creased sympathetic activity16 or a combination of
both.
In patients with COPD, increased airway resis-
tance and work of breathing has been proposed as a
mechanism explaining the autonomic nervous dys-
function.14 According to this hypothesis, sympatho-
vagal imbalance (increased sympathetic tone and
decreased parasympathetic tone) would facilitate
breathing in COPD patients, promoting bigger
airway caliber. However, there is a price to pay
for this: autonomic imbalance may lead to greater
mortality risk in COPD by contributing to the
development of cardiac arrhythmias,31 the wasting
process10 and possibly the altered cardiac function.
Hypoxemia, a well recognized cause of peripheral
neuropathy,32 also influences parasympathetic
function. However, as exemplified by our study, in
which most patients were normoxemic at rest and
where we found no correlation between HRR and
resting PaO2 ; hypoxemia is not the sole factor
explaining autonomic dysfunction in COPD. Finally,
the use of inhaled ipratropium bromide, a para-
sympatholytic drug, could explain partly the
occurrence of autonomic dysfunction in COPD as
evidenced by a delayed HRR in patients with COPD.Systemic absorption of ipratropium has the poten-
tial to inhibit initial HRR, as suggested by our
results (lower HRR in anticholinergic users). How-
ever, no change in the autonomic function after
anticholinergic inhalation has been reported in
healthy subjects33 or asthmatic adults,34 although
admittedly these results were obtained in younger
subjects than those involved in the present study.
Furthermore, the Lung Health Study I failed to show
a statistically significant association between ipra-
tropium and mortality in COPD despite following a
large group of patients for a relatively long period
of time.28,29Methodological considerations
Based on the lower limit of the 95% confidence
interval of HRR in healthy subjects, we defined HRR
as abnormal when it wasp14 beats. This threshold
has a strong physiological and statistical rationale.
First, it is consistent with a previously published
study in which cut off points of 12–18 beats have
been validated as significant predictors of mortal-
ity.21 Second, we also used a statistical model to
determine the best cut-off point to predict
mortality (change-point model for hazard function
as proposed by Muller and Wang).35 With this
method, the maximum likelihood ratio w2 value is
used to estimate the value where there is a shift in
the hazard function. The threshold that provided
the strongest association with mortality was a HRR
of 14 beats, also corresponding to the lower limit of
the 95% confidence interval in healthy subjects.
Furthermore, the validity of the association be-
tween a low HRR and mortality in COPD was
reinforced by the fact that all HRR thresholds
between 12 and 16 beats were significant predic-
tors of mortality.
To our knowledge, even if verapamil, diltiazem
and digoxin are known to reduce heart rate, their
effects on HRR have never been reported. The
tendency of patients using these drugs to have a
lower HRR is probably not clinically relevant since
on average, HRR was abnormal (p14 beats) in both
users and non-users. Finally, HRR was still an
independent predictor of mortality even after
analyzing only patients who did not use these
drugs.
There are discrepancies between our results and
Volterrani et al.’s finding of an increased para-
sympathetic activity in COPD patients.14 In their
study, parasympathetic tone was evaluated from
heart rate variability during controlled breathing
at 15 breaths/min, a non-physiologic breathing
pattern, particularly in patients with COPD.
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withdrawn from treatment with aminophylline,
prednisone and b2-agonists 24 h before the study
and may thus have demonstrated some reflex
withdrawal effects.36
Apart from parasympathetic tone, breathing
pattern may also influence HRR. Breathing at high
lung volume (hyperinflation) coupled with in-
creased pleural deflection during inspiration could
be expected to slow down HRR.37 Although it would
be extremely difficult to design an experiment to
perfectly control the potential impact of breathing
pattern and operating lung volume on HRR in COPD,
the absence of difference in breathing patterns at
one minute post exercise (respiratory rate, ventila-
tion and tidal volume) in patients with normal and
abnormal HRR suggests that these variables are not
the main mechanism explaining a low HRR in our
patients.
Correlation analyses never prove causality. Since
functional status is also an important determinant
of survival in COPD, it was important to ensure that
HRR was independent from peak exercise capacity.
In this regard, Imai et al. found that HRR 30 s after
peak exercise (vagally mediated) was nearly in-
dependent of exercise intensity, but that HRR 2min
after peak exercise largely depended on the
exercise workload.26 However, Cole et al. found
that a decrease in exercise capacity (assessed in
METs) was an independent predictor of HRR. In our
study, no significant relationship was found be-
tween HRR and peak work capacity in healthy
subjects. The correlation between these para-
meters in COPD patients was weak, peak work
capacity explaining only 13% of the variance in
HRR. Based on this, abnormal HRR in our patients
did not seem to be mediated mostly by peak
exercise capacity.
Although low body weight may predict to some
extend mortality in COPD, we have recently shown
that it is the loss in muscle mass that explains the
association between low body weight and poor
survival.10 Given that muscle wasting can occur
independently from body weight loss in patients
with COPD,38 we speculate that the lack of
association between body mass index and survival
in our study could be related to some disparity
between body weight and muscle mass. Unfortu-
nately, muscle mass was not directly assessed in
this cohort of patients.
In conclusion, a low HRR is a common finding in
COPD patients and is associated with decreased
survival in these individuals. HRR may thus repre-
sent an easily measurable prognostic marker in
COPD. The present study provides a strong basis to
undertake a prospective validation of these results.Acknowledgments
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